Markets Stocks Economy Crypto Earnings Banking Energy
Stocks · Latest

Stocks

Single names, sectors, valuations and the trades behind the tape, explained in plain language.

ResMed Sells MatrixCare for $490M to Sharpen Focus on Sleep and Home Care
Stocks

ResMed Sells MatrixCare for $490M to Sharpen Focus on Sleep and Home Care

ResMed is selling its MatrixCare healthcare software unit to private equity firm Frazier Healthcare Partners for $490 million in cash. The d

Eleanor Whitfield ·
Orezone Gold Sets First Production Targets for Casa Berardi Mine, Plans Major Drill Program
Stocks

Orezone Gold Sets First Production Targets for Casa Berardi Mine, Plans Major Drill Program

Orezone Gold has issued its first operating targets for the recently acquired Casa Berardi mine, projecting 62,000-67,000 ounces at $2,600-$

Marcus Devlin ·
First Majestic Silver Sells San Martin Mine for $90 Million in Deferred Deal
Stocks

First Majestic Silver Sells San Martin Mine for $90 Million in Deferred Deal

First Majestic Silver has agreed to sell its San Martin silver mine in Mexico for $90 million in cash. Most of the payment is deferred until

Eleanor Whitfield ·
Coty to Hand Gucci Beauty Back to Kering in $400 Million Deal, Pay Down Debt
Stocks

Coty to Hand Gucci Beauty Back to Kering in $400 Million Deal, Pay Down Debt

Coty is selling the Gucci Beauty license back to parent company Kering for $400 million. It will keep operating the brand until mid-2027, th

Marcus Devlin ·
Strategy Explores Preferred Share Swap with Distressed Debt Funds After 75% Plunge
Stocks

Strategy Explores Preferred Share Swap with Distressed Debt Funds After 75% Plunge

Strategy is weighing a deal to let investors swap its battered preferred shares for new preferreds at a discount or common stock. The move f

Marcus Devlin ·
Healthcare Stocks Rally as Vertex's $10B Crinetics Deal Resets Biotech Buyout Math
Stocks

Healthcare Stocks Rally as Vertex's $10B Crinetics Deal Resets Biotech Buyout Math

Healthcare stocks climbed Tuesday as Vertex sealed a $10 billion deal for Crinetics, lifting biotech ETFs. Eli Lilly and Vera Therapeutics a

Eleanor Whitfield ·
Consumer Stocks Split as Staples Rise, Discretionary Slip Ahead of July 4th
Stocks

Consumer Stocks Split as Staples Rise, Discretionary Slip Ahead of July 4th

Consumer stocks showed a split ahead of July 4th: staples rose 0.9% while discretionary fell 0.8%. Redbook reported same-store sales up 11.5

Marcus Devlin ·
O'Reilly's Potential NAPA Deal: $16B Boost but Regulatory and International Hurdles
Stocks

O'Reilly's Potential NAPA Deal: $16B Boost but Regulatory and International Hurdles

Truist analysts suggest O'Reilly Automotive could acquire Genuine Parts' NAPA auto-parts business, adding $16 billion in sales. However, FTC

Eleanor Whitfield ·
RBC Boosts Tesla Target to $500, Citing Potential SpaceX Takeover Premium
Stocks

RBC Boosts Tesla Target to $500, Citing Potential SpaceX Takeover Premium

RBC Capital Markets lifted its Tesla price target to $500, pointing to a hypothetical all-stock acquisition by SpaceX that could include a 2

Eleanor Whitfield ·
Georg Fischer Sells Foundry Unit for 220M Francs; Givaudan Buys Stake in Microcaps
Stocks

Georg Fischer Sells Foundry Unit for 220M Francs; Givaudan Buys Stake in Microcaps

Swiss stocks were little changed as industrial group Georg Fischer sold its aerospace foundry unit for 220 million francs, and fragrances ma

Marcus Devlin ·
S&P Global Restructures Reporting Segments Ahead of Mobility Spinoff; RBC Sees Limited Margin Impact
Stocks

S&P Global Restructures Reporting Segments Ahead of Mobility Spinoff; RBC Sees Limited Margin Impact

S&P Global is reorganizing its business reporting segments ahead of its planned Mobility spinoff. RBC Capital Markets says the changes shoul

Marcus Devlin ·
BofA Warns Tougher Q2 Scrutiny for Moderna, TG Therapeutics, Agios on Launch Execution
Stocks

BofA Warns Tougher Q2 Scrutiny for Moderna, TG Therapeutics, Agios on Launch Execution

Bank of America Securities warns that Moderna, TG Therapeutics, and Agios Pharmaceuticals will face tougher questions in Q2 earnings about w

Eleanor Whitfield ·